Telix shares are nearing a record high on Wednesday…
The post Telix (ASX:TLX) share price jumps 7% on major Merck collaboration appeared first on The Motley Fool Australia. –
The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been a very strong performer on Wednesday.
The molecularly targeted radiation (MTR) focused biopharmaceutical company’s shares have jumped 7% to $6.53 today.
This means the Telix share price is now trading close to its record high of $6.65.
Why is the Telix share price storming higher?
The Telix share price is being bid higher by investors today following the release of a promising announcement this morning.
According to the release, the company has entered into a pan-cancer clinical collaboration with pharmaceutical giant Merck. This builds on the success of a strategic research collaboration agreement between the two companies in 2019.
The release explains that the agreement will see the two parties conduct combination studies with one of Merck’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 and TLX250 MTR therapeutic programs.
TLX591 and TLX250 are late-stage products in development for prostate and renal cancer therapy, respectively. The collaboration will investigate the synergy of these investigational assets with Merck’s DDRi compound across a wide variety of oncology indications.
“The vanguard of nuclear medicine and oncology”
Telix’s CEO, Dr. Christian Behrenbruch, appeared to be very pleased with the agreement.
He said: “This collaboration represents the vanguard of nuclear medicine and oncology, and we are excited by the level of new data and intellectual property already generated, which is highly supportive of clinical translation.”
“Pre-clinical studies provide evidence that the combined effect of Merck’s DDRi compound with Telix’s MTR candidates has potential to significantly impact cancer by improving efficacy and reducing the required radiation dose for tumour reduction and remission, compared to MTR only,” Dr Behrenbruch added.
Today’s gain means the Telix share price is smashing the market in 2021 and now up over 60% year to date.
Should you invest $1,000 in Telix right now?
Before you consider Telix, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Motley Fool contributor James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.